Adipose tissue.Pathophysiology, distribution, sex differences and the role in inflammation and cancerogenesis;Tkanka tluszczowa. Patofizjologia, rozmieszczenie, róznice plciowe oraz znaczenie w procesach zapalnych i nowotworowych

Endokrynologia Polska

Volumn 58, Issue 4, 2007, Pages 330-342

  Sieminska, Lucyna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipokines; Adipose tissue: Visceral; Brown; Cancerogenesis; Inflammatory process; Subcutaneous

Indexed keywords

ADIPOCYTOKINE;

ADIPOCYTE; ADIPOSE TISSUE; BODY FAT DISTRIBUTION; HUMAN; INFLAMMATION; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RISK FACTOR; SEX DIFFERENCE;

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; BODY FAT DISTRIBUTION; HUMANS; INFLAMMATION; NEOPLASMS; RISK FACTORS; SEX FACTORS;

EID: 38449123114     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Kilroy GE, Foster SJ, Wu X i wsp. Cytokine profile of human adipose-derived stem cells: Expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol 2007; 212: 702-709.
2. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007; 100: 1249-1260.
3. Schaffler A, Muller-Radner U, Scholmerich J i wsp. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006; 27: 449-467.
4. Nedergaard J, Petrovic N, Lindgren EM i wsp. PPARgamma in the control of brown adipocyte differentiation. Biochim Biophys Acta 2005; 1740: 293-304.
5. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004; 84: 277-359.
6. Bogacka I, Xie H, Bray GA i wsp. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004; 27: 1660-1667.
7. Wolf G. The mechanism and regulation of fat mobilization from adipose tissue: desnutrin, a newly discovered lipolytic enzyme. Nutr Rev 2005; 63: 166-70.
8. Sengenes C, Stich V, Berlan M i wsp. Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women. Int J Obes Relat Metab Disord 2002; 26: 24-32.
9. Dobins RL, Szczepaniak LS, Zhang W i wsp. Chemical sympathectomy alters regulation of body weight during prolonged ICV leptin infusion. Am J Physiol Endocrinol Metab 2003; 284: E778-E787.
10. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5159-5165.
11. Shimada M, Shimano H, Gotoda T i wsp. Overexpression of human lipoprotein lipase in transgenic mice. J Biol Chem 1993; 268: 17924-17929.
12. Cnop M, Landchild MJ, Vidal J i wsp. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002; 51: 1005-1015.
13. Giorgino F, Laviola L, Eriksson JW. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand 2005; 183: 13-30.
14. Ferrara CM, Lynch NA, Nicklas BJ i wsp. Differences in adipose tissue metabolism between postmenopausal and perimenopausal women. J Clin Endocrinol Metab 2002; 87: 4166-4170.
15. Tchernof A, Belanger C, Morisset AS i wsp. Regional differences in adipose tissue metabolism in women: minor effect of obesity and body fat distribution. Diabetes 2006; 55: 1353-1360.
16. Adams M, Montague CT, Prins JB i wsp. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
17. Bays H. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197-1211.
18. Tankó LB, Bagger ZY, Alexandersen P i wsp. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003; 107: 1626-1631.
19. Van Pelt RE, Jankowski CM, Gozansky WS i wsp. Lower-body adiposity and metabolic protection in postmenopausal women J Clin Endocrinol Metab 2005; 90: 4573-4578.
20. Van Pelt RE, Evans EM, Schechtman KB i wsp. Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrinol Metab 2002; 282: E1023-E1028.
21. Tanko LB, Bruun JM, Alexandersen P i wsp. Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity. Circulation 2004; 110: 2246-2252.
22. Perez RA. Liposuction and diabetes type 2 development risk reduction in the obese patient. Med Hypotheses 2007; 68: 393-396.
23. Klein S, Fontana L, Young VL i wsp. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Eng J Med 2004; 350: 2549-2557.
24. Simka M. Liposuction and diabetes type 2 development risk reduction. Med. Hypotheses 2007; 69: 958-959.
25. Weber RV, Buckley MC, Fried SK i wsp. Subcutaneous lipectomy causes a metabolic syndrome in hamsters. Am J Physiol Regul Integr Comp Physiol 2000; 279: R936-R943.
26. Maffei L, Murata Y, Rochira V i wsp. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004; 89: 61-70.
27. Soler JT, Folsom AR, Kaye SA i wsp. Associations of abdominal adiposity, fasting insulin, sex hormone binding globuline, and estrone with lipids and lipoproteins in post-menopausal women. Atherosclerosis 1989; 79: 21-27.
28. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
29. Cooke PS, Naaz A. Role of estrogens in adipocyte development and function. Exp Biol Med. 2004; 229: 1127-1135.
30. Ramirez ME, McMurry MP, Wiebke GA i wsp. Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. Metabolism 1997; 46: 179-185.
31. Milewicz A, Jedrzejuk D. Climacteric obesity: from genesis to clinic. Gynecol Endocrinol 2006; 22: 18-24.
32. McInnes KJ, Corbould A, Simpson ER i wsp. Regulation of adenosine 5', monophosphate-activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen-deficient state. Endocrinology 2006; 147: 5907-5913.
33. Nishizawa H, Shimomura I, Kishida K i wsp. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741.
34. Siemińska L, Wojciechowska C, Niedziołka D i wsp. Effect of postmenopause and hormone replacement therapy on serum adiponectin levels. Metabolism 2005; 54: 1610-1614.
35. Combs TP, Berg AH, Rajala MW i wsp. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 2003; 52: 268-276.
36. Gui Y, Silha JV, Murphy LJ. Sexual dimorphism and regulation of resistin, adiponectin, and leptin expression in the mouse. Obes Res 2004; 12: 1481-1491.
37. Machinal-Quelin F, Dieudonne MN, Pecquery R i wsp. Direct in vitro effects of androgens and estrogens on ob gene expression and leptin secretion in human adipose tissue. Endocrine 2002; 18: 179-184.
38. Ling C, Kindblom J, Wennbo H i wsp. Increased resisitn expression in the adipose tissue of male prolactin transgenic mice and in male mice with elevated androgen levels. FEBS Lett. 2001; 507: 147-150.
39. Bélanger C, Luu-The V, Dupont P i wsp. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res 2002; 34: 737-745.
40. Corbould AM, Judd SJ, Rodgers RJ. Expression of types 1, 2, and 3 17b-hydroxysteroid dehydrogenase in subcutaneous abdominal and intraabdominal adipose tissue in women. J Clin Endocrinol Metab 1998; 83: 187-194.
41. Wake DJ, Strand M, Rask E i wsp. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 2007; 66: 440-446.
42. Lacasa D, Taleb S, Keophiphath M i wsp. Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology 2007; 148: 868-877.
43. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Zurakowski A i wsp. The role of tumor necrosis factor (TNF-a) in control of metabolism. Wiad Lek 2005; 1005, 58: 670-674.
44. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J i wsp. Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131-1134.
45. Varma V, Yao-Borengasser A, Rasouli N i wsp. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007; 92: 666-672.
46. Skurk T, Alberti-Huber C, Herder C i wsp. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033.
47. Pajvani UB, Hawkins M, Combs TP i wsp. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvment insulin sensitivity. J Biol Chem 2004; 279: 12152-12162.
48. Tataranni PA, Ortega E. A burning question. Does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes 2005; 54: 917-927.
49. Mazurek T, Zhang L, Zalewski A i wsp. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003; 108: 2460-2466.
50. Schaffler A, Landfriend K, Volk M i wsp. Potential of adipocytokines in predicting peripancreatic necrosis and severity in acute pancreatitis: pilot study. J Gastroenterol Hepatol 2007; 22: 326-334.
51. Kumar S, Coenen MJ, Scherer PE i wsp. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 2004; 89: 930-935.
52. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591.
53. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-783.
54. Wiwanitkit V. Interaction between leptin and leptin receptor in gastric carcinoma: Gene ontology analysis. Rev Esp Enferm Dig 2007; 99: 201-205.
55. Horiguchi A, Sumitomo M, Asakuma J i wsp. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol 2006; 176: 1631-1635.
56. Pai R, Lin C, Tran T i wsp. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem Biophys Res Commun 2006; 331: 984-992.
57. Ishikawa M, Kitayama J, Nagawa H. Expression pattern of leptin and leptin receptor (OB-R) in human gastric cancer. World J Gastroenterol 2006; 12: 5517-5522.
58. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006; 340: 1158-1166.
59. Tworoger SS, Eliassen AH, Kelesidis T i wsp. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrin Metab 2007; 92: 1510-1516.